Press "Enter" to skip to content

Explained: What Covaxin’s 81% interim vaccine efficacy means?

Bharat Biotech on Wednesday announced its Covid-19 vaccine candidate BBV152 Covaxin demonstrated 81% interim vaccine efficacy in its Phase 3 clinical trial.

Original source: https://health.economictimes.indiatimes.com/news/pharma/81329879?utm_source=RSS&utm_medium=ETRSS

Also Read:   2 major pharma companies announce to co-develop potential COVID 19 vaccine